Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial
Follows Earlier Positive Phase I Clinal Data For Biosimilar Rival To Lantus
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
